VR Logo

TCR2 Therapeutics Inc. (TCRR) download report


Healthcare | Biotechnology & Pharma Research

TCR2 Therapeutics Inc. (TCRR) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.

IPO Date: 14-Feb-2019

Pres, CEO & Director: Dr. Garry E. Menzel M.B.A., Ph.D.

Founder & Member of the Advisory Board: Dr. Patrick A. Baeuerle Ph.D.

Listing: NASDAQ: TCRR

Country: United States

Headquarters: Cambridge, MA

Website: https://www.tcr2.com

Key Facts

Market cap: $112.17 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-107.42 Mln

Cash: $232.19 Mln

Total Debt: $53.68 Mln

Insider's Holding: 0.89%

Liquidity: Low

52 Week range: $2.07 - 19.03

Shares outstanding: 38,546,300

6 Years Aggregate:

  • CFO: $-219.90 Mln
  • EBITDA: $-262.95 Mln
  • Net Profit: $-261.77 Mln

Stock Performance

Time Period TCR2 Therapeutics (TCRR) S&P BSE Sensex S&P Small-Cap 600
YTD-36.05-8.99-18.91
1 month29.57-3.40-8.99
3 months10.78-8.50-16.26
1 Year-81.960.89-17.04
3 Years-40.7310.416.04
5 Years--11.435.85
10 Years--11.779.82
As on 30-Jun-2022
Year TCR2 Therapeutics (TCRR) S&P Small-Cap 600 S&P BSE Sensex
2021-84.9325.2721.99
2020116.609.5715.75